## A reliable resource for cancer research: Regina Elena Biobank

Laura Conti<sup>1</sup>, Chiara Mandoj<sup>1</sup>, Simona di Martino<sup>2</sup>, Valentina Laquintana<sup>2</sup>, Giulia Orlandi<sup>1</sup>, Mustapha Haoui<sup>1</sup>, Mirella Marino<sup>2</sup>, Giovanni Cigliana<sup>1</sup>, Edoardo Pescarmona<sup>2</sup>, Gennaro Ciliberto<sup>3</sup>

Body Fluids Biobank, Clinical Pathology, <sup>2</sup> Tissue Biobank, Department of Pathology, <sup>3</sup> Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome Italy


BACKGROUND: A biobank may be defined as the collection, processing and long-term storage of biological samples for research purposes. The availability of well annotated, high-quality human samples linked to accurate diagnostic and clinical information is essential in the research and development of new biomarkers and drugs in the overall goal of personalized medicine. We are currently engaged in establishing and developing an Institutional Biobank (BBIRE) whose essential function is to collect tissue (T) and body fluids (LB) samples in accordance with standardized criteria and cryoconserve them in order to provide biological material for approved cancer research projects.

METHODS & RESULTS: In order to meet the requirements of quality and traceability of biological samples, different protocols are utilized for the samples crioconservation, using tubes with 2D codes and dedicated IT infrastructure (software, barcode readers). In this way we are able to manage the transportation, handling and information storage of biological samples and to update follow-up and associated data. BBIRE includes a Steering Committee and an Operating Group. A broad Informed consent has been drawn up, submitted to the Ethics Committee, subsequently validated and added to the medical record. More than 24200 aliquotes of whole blood, serum, EDTA plasma and citrate plasma from 940 patients with lung and breast cancer, soft tissue sarcoma, bone tumors, head and neck cancers, brain tumors, thymoma and melanoma have been collected in the BBIRE-LB taken at first diagnosis and at different therapeutic stages. More than 400 Tumor tissue samples (Fresh frozen, OCT, FFPE and Cells) have been collected with procedures that guarantee both quality of the pathological diagnosis as well as the biological integrity of macromolecules (DNA, RNA and proteins).

CONCLUSIONS: An improvement of such relevant core facilities in term of the development of standardized methodologies for the acquisition of the most appropriate samples required for new approaches to research such as "liquid biopsy", targeted therapy and biomarkers validation is going on


due to the coordinated activity of the biobanking team.








Tumor and ctDNA analysis for personalized cancer performed detection and monitoring is biobank samples




Cancer patient selection

**IRE Biobank Workflow** 




specific informed consent is proposed to the patient



Sample collection, clinical and biological data are recorded and managed by dedicated software

## **SAFETY PRIVACY TRACEABILITY**







A request for banking of biological fluids is addressed through the creation of an electronic page Computer Order Entry (GALILEO) to the BioBank



After checking and testing for biomaterial conformity, the samples are processed and stored according to standard operating procedures (SOP)





Radical or diagnostic surgery is performed and the sterile tissue speciment is immediately addressed to the Pathology Department and sampled by dedicated pathology.



Blood samples are withdrawn by Research Nurses in the Surgery ward (prior to operation) and outpatient (during follow-up)



